Business & Regulation

A round-up of the latest expansion plans and new facilities as building fever grips the industry

Big pharma is turning to outside sources to fill pipelines, but how often are companies backing the wrong horse?

How did the NIH get it so wrong – and how can it move on?

Rising drug prices are not helping the industry’s image problem.

Pharmaceutical and regulatory professionals around the world must speak the same language.

Is pharma keeping up with the latest innovations? US legislators say no, and are looking to a new act to accelerate approvals.

Sitting Down With... Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon, India.

In this paper, the authors describe the use of laser diffraction to analyse dry powder behaviour.

The rise of biosimilars is great news for overburdened healthcare systems, but it’s a very different proposition to a simple generic.

Sitting Down With… David Pyott, Former Chairman of the Board and Chief Executive Officer of Allergan, Inc.